SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 31, 2026

FENC

FENNEC PHARMACEUTICALS INC.
NEUTRAL
Impact 4/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $1.0M total
Actionable Insight • Neutral

The selling is modest and involves only two executives, making it unlikely to signal a material negative event. Monitor for any upcoming corporate announcements (e.g., earnings, pipeline updates) that could provide context; if additional insider sales emerge at higher volumes, reassess.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+20d ⚠ clustered
FENC ▼ -11.14% at T+20d
NEUTRAL call -11.14% · α vs SPY -12.32% · entry $12.03 → $10.69
Next anchor: T+60d in 29d
Latest observation: T+37 -24.13% FF3 residual α
Entry = T+0 close
Aug 31, 2026
via day close
T+1d
+2.33%
call +2.33% · α +1.88%
$12.31
settled 8w ago
T+5d
-3.16%
call -3.16% · α -3.24%
$11.65
settled 7w ago
T+20d
-11.14%
call -11.14% · α -12.32%
$10.69
settled 27d ago
T+60d
Pending
in 29d

Price Chart

Loading chart...

Executive Summary

Two Fennec Pharmaceuticals executives (CFO and CMO) sold a combined $1.03M in open-market shares over a 5-day window, representing ~0.24% of market cap. The sales are modest in size and not accompanied by any material negative corporate news, suggesting routine portfolio diversification rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$1.0M
Insiders
2

Key Facts

  • CFO Robert Andrade sold 75,000 shares at $11.78 for $883,500 on 2026-08-27
  • CMO Sayad Pierre Sargis sold 12,000 shares at $12.18 for $146,160 on 2026-08-31
  • Total open-market sales: $1,029,660 (0.24% of $430M market cap)
  • Non-cash grants/awards also occurred on 2026-08-31 (no economic impact)
  • CFO also exercised options on 2026-08-28 (non-cash event)

Financial Impact

Insider sales of $1.03M represent 0.24% of market cap — modest and not indicative of material negative information

insider ownershipfloat

Risk Factors

  • Further insider selling could indicate deteriorating confidence
  • No explicit catalyst identified — sales may be liquidity-driven

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-FENC-1788221754065
18 reports for FENC
Performance horizon
100% Hit rate @ T+60 3 of 3 directional calls Went positive at some point 4 of 5 best @ T+60▲ +50.50%Mar 24, 2026
Filters
Rows
Reports for FENC — sortable, filterable
TypeNow
Oct 19, 2026
7d ago
SC 13G/A
BULLISH ★ 5/10
$10.27awaiting T+60—$10.15 (−1.17%)
Aug 31, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$12.03awaiting T+60—$10.15 (−15.63%)
Aug 31, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$12.03awaiting T+60—$10.15 (−15.63%)
Aug 11, 2026
10w ago
Press Release
BULLISH ★ 6/10
$12.78awaiting T+60—$10.15 (−20.58%)
Jun 15, 2026
19w ago
Press Release
NEUTRAL ★ 2/10
$9.19 $11.65▲ +26.77%▲ +25.77%$10.15 (+10.45%)
May 22, 2026
22w ago
8-K
NEUTRAL ★ 4/10
$9.89 $11.87▲ +20.02%▲ +17.30%$10.15 (+2.63%)
May 18, 2026
23w ago
8-K
NEUTRAL ★ 2/10
$9.76 $12.06▲ +23.57%▲ +17.28%$10.15 (+4.00%)
May 14, 2026
23w ago
Press Release
BULLISH ★ 6/10
$9.24 $10.94▲ +18.40%▲ +14.81%$10.15 (+9.85%)
May 7, 2026
24w ago
Press Release
NEUTRAL ★ 1/10
$6.90 $9.59▲ +38.99%▲ +35.15%$10.15 (+47.10%)
Apr 28, 2026
25w ago
8-K
NEUTRAL ★ 2/10
$6.26 $9.99▲ +59.58%▲ +55.47%$10.15 (+62.14%)
Showing 10 of 18

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026